For example, some ER+ patients with Luminal A breast cancer will live for over 10 years without experiencing breast cancer recurrence when treated with adjuvant tamoxifen despite exhibiting high grade, lymph node invasion, and overall higher recurrence risk, while other ER+ patients in the Basal subtype all relapse within 5 years [5]. Here, ESR1 is linked to breast cancer.